Novartis Bets $12 Billion on Avidity Biosciences to Pioneer Muscle-Targeted RNA Therapies

In a $12 billion move that strengthens its neuroscience and rare disease portfolio, Novartis is acquiring Avidity Biosciences to anchor its push into next-generation RNA medicines. The deal positions Novartis at the forefront of muscle-targeted therapeutics and reflects the broader industry shift toward specialty-focused drug development. For Novartis, the acquisition offers…